Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Jay-Bradner"

3 News Found

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
Diagnostic Center | July 01, 2025

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Biotech | March 09, 2022

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders

Novartis announces next-generation CAR-T platform, T Charge
Biotech | December 14, 2021

Novartis announces next-generation CAR-T platform, T Charge

T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies

Latest Stories

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging